— Vertex Pharmaceuticals (NASDAQ: VRTX) reported third-quarter 2019 earnings of $1.23 per share, vs. $1.15 per share expected
— Total revenue grew 21% to $949.8 million, vs $950.9 million expected.
— Reiterated FY19 product revenues guidance of $3.70 – 3.75 billion. Non-GAAP effective tax rate outlook was also unchanged at 21-22%.
— VRTX shares were down 0.14% immediately following the announcement.
The retail environment has witnessed many changes in customers’ shopping behavior lately, especially after the COVID outbreak. With inflation putting pressure on personal finances, there appears to be a new
Shares of Dollar General Corporation (NYSE: DG) were up over 2% on Friday, a day after the company delivered mixed results for the third quarter of 2022 and lowered its
For technology stocks, 2022 has been a challenging year, with companies losing significant market value amid prolonged stock selloff. In that respect, Salesforce, Inc. (NYSE: CRM) is among the worst-affected